iMOST (Instant Mobile Self-Test), Transforming Digital Health and Beyond
Accurate Instant Mobile Health Self-Test at Your Finger Tips, Anywhere, Anytime, Available and Affordable To Everyone
Press Release (5/20/2021): Essenlix Partners with Roche Diagnostics Norway to Employ Essenlix’s iMOSTTM Platform for Patient At-Home Test Market
Press Release (7/14/2021): Essenlix Appoints Dieter Weinand, Former Bayer, Pfizer, and Sanofi Executive, as Executive Chairman
iMOST Video
Press Release (5/20/2021): Essenlix Partners with Roche Diagnostics Norway to Employ Essenlix’s iMOSTTM Platform for Patient At-Home Test Market
Press Release (7/14/2021): Essenlix Appoints Dieter Weinand, Former Bayer, Pfizer, and Sanofi Executive, as Executive Chairman
iMOST Video
Essenlix, a digital health and wellness company, provides a game-changing instant mobile health self-test platform, iMOST, that allows any person to accurately perform a diagnostic/health test her/himself, anywhere, anytime, using a single drop of body fluid and a smartphone, all within 60 seconds, at a low cost, with the result sent immediately to professionals.
iMOST™ (Instant Mobile Self-Test), first of the type, is based on outside-the-box thinking and a fundamentally different paradigm. The new paradigm is realized through uniquely implementing nanotechnology, advance imaging, artificial intelligence/machine learning and new bio/chemical processes into diagnostic testing. iMOST delivers clinical lab-quality test results using a simple device, even when a sample, device, process, and operation are imperfect.
Diagnostic lab-testing is a vital and necessary procedure for diagnosing diseases and monitoring health conditions. The iMOST platform is removing one of the largest barriers in digital health by replacing a conventional inconvenient, time consuming, and expensive lab-test with an instant mobile self-test platform. Essenlix aims to make iMOST available to most of the world’s 7 billion population.
iMOST™ (Instant Mobile Self-Test), first of the type, is based on outside-the-box thinking and a fundamentally different paradigm. The new paradigm is realized through uniquely implementing nanotechnology, advance imaging, artificial intelligence/machine learning and new bio/chemical processes into diagnostic testing. iMOST delivers clinical lab-quality test results using a simple device, even when a sample, device, process, and operation are imperfect.
Diagnostic lab-testing is a vital and necessary procedure for diagnosing diseases and monitoring health conditions. The iMOST platform is removing one of the largest barriers in digital health by replacing a conventional inconvenient, time consuming, and expensive lab-test with an instant mobile self-test platform. Essenlix aims to make iMOST available to most of the world’s 7 billion population.